Rezulin

Do not discontinue the use of any medication without first consulting your physician.

Rezulin® was the brand name for troglitazone, which was approved for the treatment of Type 2 Diabetes. Rezulin® was designed to improve the body’s capacity for using its naturally occurring insulin, preventing the hyperglycemia (high blood sugar) that can lead to kidney damage, eye disease, and nerve damage.

Rezulin® generates high levels of toxicity in the liver and poses a serious risk of liver damage. In 1999, the FDA required a warning label regarding potential liver damage. Despite these new labels and an advisory that Rezulin® should only be prescribed to patients whose diabetes did not respond to other drugs, the number of liver complications among Rezulin® users continued to rise. In 2000, the FDA mandated that Rezulin®’s manufacturer, Parke-Davis, remove the drug from the market.

If you or a loved one took Rezulin® and suffered liver problems, contact a John Bales Florida drug injuries lawyer today. Complete a FREE Online Consultation Form or call us toll free 1-800-CALL JOHN (1-800-225-5564) 24 hours, 7 days a week.

Consult with your physician if you have questions concerning this medication. This article is for informational purposes only. It is not intended to constitute medical advice and should not be viewed as such. For medical advice, you should always consult with your physician.

Rezulin® is a registered trademark of Parke-Davis Pharmaceuticals, Ltd. and is used here only for the purpose of identifying the product in question. This law firm is not affiliated with, sponsored by, or associated with Parke-Davis Pharmaceuticals, Ltd. or the FDA.